Jump to content

Catherine Llorens-Cortes

Add links
From Wikipedia, the free encyclopedia
Catherine Llorens-Cortès
Born (1954-01-06) January 6, 1954 (age 70)
Alma materPierre and Marie Curie University
Scientific career
InstitutionsINSERM
Collège de France
ThesisLocalisation des sites de reconnaissance des endorphines sur les systemes catecholaminergiques cerebraux; leur role eventuel dans le developpement de la tolerance et de la dependance a la morphine (1978)

Catherine Llorens-Cortès (née Lepart; born January 6, 1954) is a French pharmacologist who is a Professor and Director of the Central Laboratory of Neuropeptides and Water and Cardiovascular Regulations at the Collège de France. Her research considers neuropharmacology and the development of new therapies for people with heart conditions. She was awarded the French Academy of Sciences Medal for Applications of Science in 2023.

Early life and education

[edit]

Llorens-Cortès was born in Saint-Germain-en-Laye. She was a doctoral researcher at the Pierre and Marie Curie University, where she studied endorphin recognition and response to morphine.[1] After earning her doctorate she was appointed to a permanent research position at L'Institut national de la santé et de la recherche médicale (INSERM), where she eventually became research director. [citation needed]

Research and career

[edit]

Llorens-Cortès has been interested in biologically active peptides since the start of her career. She has mainly worked on enzymes that are involved with the degradation or activation of active peptides.[2] In 2011, Llorens-Cortès integrated her laboratory into the Collège de France Interdisciplinary Center for Research in Biology.[2] She developed endogenous morphines that were developed into an anti diarrhoea drug used in paediatrics.[2] Her research considers new drugs for hypertension, hyponatremia and heart failure.[3][4] She developed Firibastat, an aminopeptidase that can penetrate the brain, normalise blood pressure and improve cardiac function.[5] Firibastat prevents left ventricular dysfunction and can improve cardiac function after myocardial infarction.[6] Llorens-Cortès also discovered apelin anaolgs (e.g. LIT01-196) to treat hyponatremia. LIT01-196 activates the apelin receptor, which is important for moderating cardiovascular function.[5]

In 2015, Llorens-Cortès co-founded Quantum Genomics, a pharmaceutical company that looks to develop new therapeutic targets for cardiovascular disease.[7]

Awards and honours

[edit]

Selected publications

[edit]
  • B P Roques; M C Fournié-Zaluski; E Soroca; J M Lecomte; B Malfroy; Catherine Llorens-Cortès; J C Schwartz (1 November 1980). "The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice". Nature. 288 (5788): 286–288. doi:10.1038/288286A0. ISSN 1476-4687. PMID 7001254. Wikidata Q59063903.
  • Zsolt Lenkei; Miklós Palkovits; Corvol P; Catherine Llorens-Cortès (1 October 1997). "Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review". Frontiers in Neuroendocrinology. 18 (4): 383–439. doi:10.1006/FRNE.1997.0155. ISSN 0091-3022. PMID 9344632. Wikidata Q41621710.
  • A Reaux; N De Mota; I Skultetyova; et al. (1 May 2001). "Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain". Journal of Neurochemistry. 77 (4): 1085–1096. doi:10.1046/J.1471-4159.2001.00320.X. ISSN 0022-3042. PMID 11359874. Wikidata Q30032204.

References

[edit]
  1. ^ "LOCALISATION DES SITES DE RECONNAISSANCE DES ENDORPHINES SUR LES SYSTEMES CATECHOLAMINERGIQUES CEREBRAUX; LEUR ROLE EVENTUEL DANS LE DEVELOPPEMENT DE LA TOLERANCE ET DE LA DEPENDANCE A LA MORPHINE | WorldCat.org". search.worldcat.org. Retrieved 2024-09-08.
  2. ^ a b c "Catherine Llorens-Cortes | Collège de France". www.college-de-france.fr (in French). 2022-04-11. Retrieved 2024-09-08.
  3. ^ Development, PodBean. "International Society of Hypertension - Interview with Dr Catherine Llorens-Cortes | The International Society of Hypertension Podcast". hypertension.podbean.com. Retrieved 2024-09-08.
  4. ^ Llorens-Cortes, Catherine; Touyz, Rhian M. (2 December 2019). "Evolution of a New Class of Antihypertensive Drugs: Targeting the Brain Renin-Angiotensin System". Hypertension. 75 (1): 6–15. doi:10.1161/HYPERTENSIONAHA.119.12675. ISSN 0194-911X.
  5. ^ a b c "Catherine Llorens-Cortes awarded with The Medal for Applications of Science 2023 - European Academy of Sciences". 2023-12-14. Retrieved 2024-09-07.
  6. ^ a b "Catherine Llorens-Cortes, lauréate 2023 de la médaille des applications des sciences | Collège de France". www.college-de-france.fr (in French). 2023-10-17. Retrieved 2024-09-08.
  7. ^ a b Wire, Actusnews. "QUANTUM GENOMICS". Actusnews Wire. Retrieved 2024-09-08.
  8. ^ "Docteur Catherine Llorens-Cortes | Cardiovascular Research Foundation - Institut de France". www.fondation-recherche-cardio-vasculaire.org. Retrieved 2024-09-08.
  9. ^ a b Décret du 13 juillet 2022 portant promotion et nomination dans l'ordre national de la Légion d'honneur, retrieved 2024-09-08
  10. ^ Décret du 31 décembre 2012 portant promotion et nomination, retrieved 2024-09-08
  11. ^ "Celebrating the Success of International Society of Hypertension Community" (PDF). 2021.
  12. ^ "Investir". lesechos-comfi.lesechos.fr. Retrieved 2024-09-08.
Retrieved from "https://wiki.riteme.site/w/index.php?title=Catherine_Llorens-Cortes&oldid=1245421869"